

Date: June 27, 2022

The Deputy General Manager, Corporate Relationships Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001	The Deputy General Manager, Listing Department, National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051
SCRIP CODE: 524372	SCRIP SYMBOL / SERIES: ORCHIDPHARMA

Sub: Qualified institutions placement of equity shares of face value Rs. 10 each (the “Equity Share(s)”) by Orchid Pharma Limited (the “Company”) under the provisions of Chapter VI of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”), and Sections 42 and 62 of the Companies Act, 2013 as amended, including the rules made thereunder (the “Issue”)

Dear Madam/Sir(s),

In the matter referred above, and in term of Regulations 29(1) and 29(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “**SEBI LODR Regulations**”), we wish to state as under -

In furtherance to our letter dated June 22, 2023 intimating you about the meeting of the Board of Directors (“**Board**”) to be held on June 27, 2023 in respect of the Issue, we wish to inform you that the Board at its meeting held today i.e. June 27, 2023 has, *inter alia*, passed the following resolutions:

- a. Approved the closure of the issue period for the Issue today i.e. June 27,2023;
- b. Determined and approved the issue price of ₹ 403.93 per Equity Share (including a premium of ₹ 393.93 per Equity Share), reflects a discount of ₹ 21.26 (i.e. 5%) on the Floor Price of ₹ 425.19 per Equity Share determined as per the formula prescribed under Regulation 176(1) of SEBI ICDR Regulations for the Equity Shares to be allotted to the eligible qualified institutional buyers in the Issue;
- c. Approved and finalized the confirmation of allocation note to be sent to the eligible qualified institutional buyers, intimating them of allocation of Equity Shares pursuant to the Issue.
- d. Approved and adopted the placement document dated June 27, 2023;
- e. Approved the issuance of refund intimation letter to the bidders who are entitled to receive the refund amount.

The meeting of the Board commenced at 16.00 hours and concluded at 21.25 hours.

We request you to take the above on record and the same be treated as compliance under the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Thanking you,

Yours truly,
For **Orchid Pharma Limited**

Marina Peter
Company Secretary
Membership No: